Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Expanded Clinical Data on AmpligenÒ in HIV Disease to be presented at the 16th International Conference on Antiviral Research
Hemispherx Presents New Data on Long-term, Post-trial Effects of RNA-based Ampligen(R) for Treatment for Chronic Fatigue Syndrome
HEMISPHERX ANNOUNCES TAGLICH BROTHERS RELEASE OF UPDATED RESEARCH REPORT
REBROADCAST OF HEMISPHERX'S JANUARY 21, 2003 CONFERENCE CALL AVAILABLE ON COMPANY'S WEBSITE OR VIA TELEPHONE REPLAY
HEMISPHERX SCHEDULES CONFERENCE CALL TO REVIEW RECENT DEVELOPMENTS IN CLINICAL TRIAL EXPANSION, STRATEGIC PARTNERSHIP SUPPORT, FUNDING AND THE OVERALL COMMERCIALIZATION PROCESS
OFFUTT SECURITIES UPDATES INDEPENDENT RESEARCH COVERAGE ON HEMISPHERX BIOPHARMA, INC.
HEMISPHERX FILES WITH REGULATORS TO REGISTER 5 MILLION SHARES OF STOCK TO SUPPORT CLINICAL TRIAL EXPANSION
Hemispherx Biopharma's International Team of Clinical Researchers to Present New Data on Experimental Treatment of CFS
Rebroadcast of Hemispherx's December 18, 2002 Conference Call Available On Company's Website or Via Telephone Replay
Hemispherx Presents New Data from Phase IIB Clinical Trial of RNA-based Ampligen® for Structured Treatment Interruption in HIV at DART Conference
73
74
75
76
77
78
79
80
81
82
83
<<
<
>
>>
Privacy